{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T13:45:40Z","timestamp":1767015940907,"version":"build-2065373602"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003921","name":"Department of Health, Australian Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.vaccine.2019.11.019","type":"journal-article","created":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T18:46:03Z","timestamp":1574448363000},"page":"1186-1193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Monitoring human papillomavirus prevalence among young Australian women undergoing routine chlamydia screening"],"prefix":"10.1016","volume":"38","author":[{"given":"Hannah","family":"Shilling","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald","family":"Murray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia M.L.","family":"Brotherton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Hawkes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Saville","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terri","family":"Sivertsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Chambers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annabelle","family":"Farnsworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne M.","family":"Garland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane S.","family":"Hocking","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7639-4355","authenticated-orcid":false,"given":"John","family":"Kaldor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Guy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steph","family":"Atchison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna-Maria","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Molano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4101-8085","authenticated-orcid":false,"given":"Dorothy A.","family":"Machalek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.11.019_b0005","unstructured":"World Health Organization, Department of immunization, vaccines and biologicals. Report of the meeting on HPV vaccine coverage and impact monitoring. Available at: http:\/\/apps.who.int\/iris\/bitstream\/10665\/70305\/1\/WHO_IVB_10.05_eng.pdf. Accessed 5 March 2016."},{"key":"10.1016\/j.vaccine.2019.11.019_b0010","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1093\/infdis\/jiy075","article-title":"Very low prevalence of vaccine human papillomavirus types among 18- to 35-year old Australian women 9 years following implementation of vaccination","volume":"217","author":"Machalek","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.11.019_b0015","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S1473-3099(14)70841-2","article-title":"Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study","volume":"14","author":"Tabrizi","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2019.11.019_b0020","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1093\/infdis\/jis590","article-title":"Fall in human papillomavirus prevalence following a national vaccination program","volume":"206","author":"Tabrizi","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.11.019_b0025","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/1741-7015-9-104","article-title":"Human papillomavirus prevalence among indigenous and non-indigenous Australian women prior to a national HPV vaccination program","volume":"9","author":"Garland","year":"2011","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2019.11.019_b0030","unstructured":"Cancer council Australia cervical cancer screening guidelines working party. National cervical screening program: guidelines for the management of screen-detected abnormalities, screening in specific populations and investigation of abnormal vaginal bleeding. Sydney: Cancer Council Australia; 2017."},{"key":"10.1016\/j.vaccine.2019.11.019_b0035","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.vaccine.2018.11.075","article-title":"Age-specific HPV prevalence among 116,052 women in Australia's renewed cervical screening program: A new tool for monitoring vaccine impact","volume":"37","author":"Brotherton","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.11.019_b0040","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-009915","article-title":"Continuing reductions in HPV 16\/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study","volume":"6","author":"Mesher","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.vaccine.2019.11.019_b0045","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1158\/1055-9965.EPI-14-0687","article-title":"Change in population prevalences of human papillomavirus after initiation of vaccination: the high-throughput HPV monitoring study","volume":"23","author":"Soderlund-Strand","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.vaccine.2019.11.019_b0050","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/S1473-3099(15)00055-9","article-title":"Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study","volume":"15","author":"Chow","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2019.11.019_b0055","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1093\/infdis\/jiy249","article-title":"The impact of the national HPV vaccination program in England using the bivalent HPV vaccine: surveillance of type-specific HPV in young females, 2010\u20132016","volume":"218","author":"Mesher","year":"2018","journal-title":"J Infect Dis"},{"year":"2015","series-title":"HIV, viral hepatitis and sexually transmissible infections in Australia annual surveillance report 2015","author":"The Kirby Institute","key":"10.1016\/j.vaccine.2019.11.019_b0060"},{"key":"10.1016\/j.vaccine.2019.11.019_b0065","unstructured":"ASHA. Australian STI management guidelines for use in primary care; 2016."},{"year":"2018","series-title":"HIV, viral hepatitis and sexually transmissible infections in Australia: annual surveillance report 2018","author":"The Kirby Institute","key":"10.1016\/j.vaccine.2019.11.019_b0070"},{"key":"10.1016\/j.vaccine.2019.11.019_b0075","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1007\/s10096-014-2147-2","article-title":"Optimization of HPV DNA detection in urine by improving collection, storage, and extraction","volume":"33","author":"Vorsters","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.vaccine.2019.11.019_b0080","unstructured":"VCS foundation. National HPV vaccination program register; 2019."},{"key":"10.1016\/j.vaccine.2019.11.019_b0085","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.pvr.2017.10.002","article-title":"HPV genotype-specific concordance between EuroArray HPV, Anyplex II HPV28 and Linear Array HPV Genotyping test in Australian cervical samples","volume":"4","author":"Cornall","year":"2017","journal-title":"Papillomavirus Res"},{"key":"10.1016\/j.vaccine.2019.11.019_b0090","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jcv.2014.01.015","article-title":"Comparison of the Anyplex II HPV28 assay with the Hybrid Capture 2 assay for the detection of HPV infection","volume":"59","author":"Kwon","year":"2014","journal-title":"J Clin Virol"},{"key":"10.1016\/j.vaccine.2019.11.019_b0095","unstructured":"Australian Bureau of Statistics: Socio-economic indexes for areas (SEIFA). ABS Catalogue no. 2033.0.55.001. Canberra; 2013."},{"key":"10.1016\/j.vaccine.2019.11.019_b0100","unstructured":"Australian Government Department of Health and Aged Care. Measuring remoteness: Accessibility\/remoteness index of Australia (ARIA) - revised edition 2011."},{"key":"10.1016\/j.vaccine.2019.11.019_b0105","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1158\/1055-9965.EPI-14-0649","article-title":"HPV type attribution in high-grade cervical lesions: assessing the potential benefits of vaccines in a population-based evaluation in the United States","volume":"24","author":"Hariri","year":"2015","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.vaccine.2019.11.019_b0110","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1158\/1055-9965.EPI-14-0410","article-title":"Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease","volume":"23","author":"Joura","year":"2014","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"10.1016\/j.vaccine.2019.11.019_b0115","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2018.23.41.1700737","article-title":"The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?","volume":"23","author":"Patel","year":"2018","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2019.11.019_b0120","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1016\/S2468-2667(16)30019-6","article-title":"Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis","volume":"1","author":"Simms","year":"2016","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.vaccine.2019.11.019_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(17)31821-4","article-title":"Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16\u201326 years: a randomised, double-blind trial","author":"Huh","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.11.019_b0130","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/S2468-2667(18)30183-X","article-title":"The projected timeframe until cervical cancer elimination in Australia: a modelling study","volume":"4","author":"Hall","year":"2019","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.vaccine.2019.11.019_b0135","doi-asserted-by":"crossref","first-page":"5753","DOI":"10.1016\/j.vaccine.2017.05.069","article-title":"Human papillomavirus vaccines: WHO position paper, May 2017-recommendations","volume":"35","author":"World Health Organisation","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.11.019_b0140","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1001\/jama.2013.1625","article-title":"Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial","volume":"309","author":"Dobson","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2019.11.019_b0145","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S1470-2045(15)00047-9","article-title":"Efficacy of fewer than three doses of an HPV-16\/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials","volume":"16","author":"Kreimer","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.vaccine.2019.11.019_b0150","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1016\/j.vaccine.2017.03.096","article-title":"Two-dose schedules for human papillomavirus vaccine: Systematic review and meta-analysis","volume":"35","author":"D'Addario","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.11.019_b0155","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1542\/peds.2009-0892","article-title":"Association between sexually transmitted diseases and young adults' self-reported abstinence","volume":"127","author":"DiClemente","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2019.11.019_b0160","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00038-019-01261-w","article-title":"Association between human papillomavirus and chlamydia trachomatis infection risk in women: a systematic review and meta-analysis","volume":"64","author":"Naldini","year":"2019","journal-title":"Int J Public Health"},{"key":"10.1016\/j.vaccine.2019.11.019_b0165","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jcv.2018.01.016","article-title":"Continuing global improvement in human papillomavirus DNA genotyping services: The 2013 and 2014 HPV LabNet international proficiency studies","volume":"101","author":"Eklund","year":"2018","journal-title":"J Clin Virol"},{"key":"10.1016\/j.vaccine.2019.11.019_b0170","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1128\/JCM.02749-13","article-title":"Comparison of Seegene Anyplex II HPV28 with the PGMY-CHUV assay for human papillomavirus genotyping","volume":"52","author":"Estrade","year":"2014","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2019.11.019_b0175","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1186\/1471-2334-14-325","article-title":"Analysis of laboratory testing results collected in an enhanced chlamydia surveillance system in Australia, 2008\u20132010","volume":"14","author":"Dimech","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2019.11.019_b0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115753","article-title":"Genital chlamydia prevalence in Europe and non-European high income countries: systematic review and meta-analysis","volume":"10","author":"Redmond","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.11.019_b0185","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S1470-2045(12)70080-3","article-title":"Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis","volume":"13","author":"Machalek","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.vaccine.2019.11.019_b0190","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1473-3099(14)70994-6","article-title":"Site-specific human papillomavirus infection in adolescent men who have sex with men (HYPER): an observational cohort study","volume":"15","author":"Zou","year":"2015","journal-title":"Lancet Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19315427?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19315427?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:41:55Z","timestamp":1759401715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19315427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0264410X19315427"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.11.019","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monitoring human papillomavirus prevalence among young Australian women undergoing routine chlamydia screening","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.11.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}